9th GCC closed forum: CAPA in regulated bioanalysis; Method robustness, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, regulatory audit experiences and electronic laboratory notebooks

15Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The 9th GCCClosed Forum was held just prior to the 2015 Workshop on Recent Issues in Bioanalysis (WRIB) in Miami, FL, USA on 13 April 2015. In attendance were 58 senior-level participants, from eight countries, representing 38 CRO companies offering bioanalytical services. The objective of this meeting was for CRO bioanalytical representatives to meet and discuss scientific and regulatory issues specific to bioanalysis. The issues selected at this year's closed forum include CAPA, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, and ELNs. A summary of the industry's best practices and the conclusions from the discussion of these topics is included in this meeting report.

Cite

CITATION STYLE

APA

Hayes, R., LeLacheur, R., Dumont, I., Couerbe, P., Safavi, A., Islam, R., … Fang, X. (2016). 9th GCC closed forum: CAPA in regulated bioanalysis; Method robustness, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, regulatory audit experiences and electronic laboratory notebooks. In Bioanalysis (Vol. 8, pp. 487–495). Future Science Ltd. https://doi.org/10.4155/bio.16.16

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free